Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 1444× Inovio Pharmaceuticals Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| IEMG | INO | |
|---|---|---|
Market Cap | $162.00B | $112.19M |
Volume | 13,446,151 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $2.65 |
52-Week Low | $64.22 | $0.66 |
Typical Hold Time | 57 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
